What is the clinical evidence from this study?

Study design: Review. Population: Erectile dysfunction and cardiovascular disease. Intervention: Cardiovascular risk stratification.

What question did this study set out to answer?

To examine erectile dysfunction as an early clinical indicator of systemic cardiovascular disease and evaluate current and emerging risk stratification strategies.

March 26, 2026Canadian Journal of Urology

From bedroom to boardroom: erectile dysfunction as a window into cardiovascular health

View Full Paper

Ask AI

Bookmark

Key result

Erectile dysfunction frequently precedes CVD by 2-5 years, signaling early systemic vascular disease.

Why the study?

Erectile dysfunction is an early harbinger of cardiovascular events, necessitating examination of its role as a vascular disease marker and a summary of cardiovascular risk stratification approaches.

Population

Men with erectile dysfunction

Design

Review

Authors

ALAndres H Guillen LozoyaMayo Clinic MBMilad Bonakdarhashemi SHSevann HeloMayo Clinic

Discussion

Member takes

Implication

Prompts CV risk assessment in men with ED; extends preventive interventions to this early high-risk group.

Key Points

To examine erectile dysfunction as an early clinical indicator of systemic cardiovascular disease and evaluate current and emerging risk stratification strategies.
Synthesized guideline recommendations, including the Princeton IV Consensus and American College of Cardiology/American Heart Association risk score stratification.
Reviewed observational cohorts, pharmacologic safety data regarding phosphodiesterase-5 inhibitors, and emerging screening modalities involving lipidomics, vascular imaging, and digital health wearables.
A 15-year retrospective analysis demonstrated that phosphodiesterase-5 inhibitor exposure was associated with a 13% lower incidence of major adverse cardiovascular events and a 25% reduction in all-cause mortality compared with non-users.
Elevated plasma ceramides were linked to an approximately 20–30% relative increase in major adverse cardiac events in the FINRISK cohort and conferred a 2- to 3-fold higher risk of cardiovascular death in the LURIC cohort.
Concomitant use of phosphodiesterase-5 inhibitors and nitrates triggers synergistic vasodilation, with hypotensive responses lasting up to 24 h after sildenafil or vardenafil and up to 48 h after tadalafil.

Structured PICO

Population

Men presenting with erectile dysfunction

Erectile dysfunction should be treated as an early clinical manifestation of systemic vascular disease, prompting comprehensive cardiovascular risk assessment and preventive interventions.

Limitations

Prospective randomized trials are essential to confirm causality of cardioprotective effects of PDE5 inhibitors.
Larger prospective studies are required to determine the incremental predictive value and clinical utility of emerging omics-based biomarkers and digital health tools.

Cite This Study

Lozoya et al. (2026) conducted a review in Erectile dysfunction and cardiovascular disease. Cardiovascular risk stratification was evaluated. Erectile dysfunction serves as an early clinical manifestation of systemic vascular disease, frequently preceding the onset of cardiovascular disease by two to five years.

synapsesocial.com/papers/69c4cdb6fdc3bde44891a5ff https://doi.org/10.32604/cju.2026.075775

Topics

Cardiovascular prevention

View Full Paper

Ask AI

Bookmark

From bedroom to boardroom: erectile dysfunction as a window into cardiovascular health

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

From bedroom to boardroom: erectile dysfunction as a window into cardiovascular health

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider